“Duration of Response and Progression-Free Survival With Sonidegib 200 Mg Once Daily Until Disease Progression or Start of New Antineoplastic Therapy in Patients With Locally Advanced Basal Cell Carcinoma: Results of the 42-Month, Randomized, Double-Blind”. SKIN The Journal of Cutaneous Medicine, vol. 4, no. 5, Sept. 2020, p. s68, https://doi.org/10.25251/skin.4.supp.67.